Exploring synoviocyte-targeted biologics and bispecific therapies for rheumatoid arthritis treatment that precisely target inflamed joints while preserving systemic immunity.
Discover how protein engineering created a high-affinity GM-CSFRα antibody to precisely target rheumatoid arthritis inflammation at its source.